Eterna Therapeutics
ERNA
31 hedge funds and large institutions have $2.44M invested in Eterna Therapeutics in 2022 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 10 reducing their positions, and 9 closing their positions.
282% more call options, than puts
Call options by funds: $42K | Put options by funds: $11K
0% less ownership
Funds ownership: 0% → 0% (-0%)
9% less funds holding
Funds holding: 34 → 31 (-3)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
57% less capital invested
Capital invested by funds: $5.66M → $2.44M (-$3.21M)
60% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LSAG
Lake Street Advisors Group
Portsmouth,
New Hampshire
|
+$1.12M |
| 2 |
Millennium Management
New York
|
+$234K |
| 3 |
Renaissance Technologies
New York
|
+$114K |
| 4 |
VF
Virtu Financial
New York
|
+$27.6K |
| 5 |
Man Group
London,
United Kingdom
|
+$20.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.49M |
| 2 |
CPWM
Cypress Point Wealth Management
Dallas,
Texas
|
-$977K |
| 3 |
NW
Naviter Wealth
Little Rock,
Arkansas
|
-$814K |
| 4 |
JP Morgan Chase
New York
|
-$331K |
| 5 |
BlackRock
New York
|
-$252K |
ERNA Hedge Fund Activity: Q3 2022 in Review
31 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q3 2022, worth a combined $2.44M — down 57% from $5.66M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of ERNA and 6 opened new positions — a net loss of 3 holders — while 10 trimmed existing stakes and 4 added.
The largest buyer was Lake Street Advisors Group, opening a new position worth an estimated $1.12M. The largest seller was Armistice Capital, cutting an estimated $1.49M.
- 31 institutional investors held Eterna Therapeutics (ERNA) as of Q3 2022, down from 34 in Q2 2022.
- Funds reported $2.44M of Eterna Therapeutics stock for Q3 2022, down 57% quarter-over-quarter.
- 6 funds opened new Eterna Therapeutics positions in Q3 2022 and 9 closed out, a net change of -3 holders.
- The largest Eterna Therapeutics buyer in Q3 2022 was Lake Street Advisors Group, an estimated $1.12M added.
- The largest Eterna Therapeutics seller in Q3 2022 was Armistice Capital, an estimated $1.49M sold.
Based on aggregated 13F filings for Q3 2022.